---
title: "CanSino Biologics, Inc. Class H (6185) Receives a Buy from UBS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291016915.md"
description: "In a report released on June 25, from UBS maintained a Buy rating on CanSino Biologics, Inc. Class H, with a price target of HK$52.40. The company’s shares closed yesterday at HK$21.34.TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. CanSino Biologics, Inc. Class H has an analyst consensus of Moderate Buy, with a price target consensus of HK$52.40."
datetime: "2026-06-27T00:26:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291016915.md)
  - [en](https://longbridge.com/en/news/291016915.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291016915.md)
generator: "portal-rs"
---

# CanSino Biologics, Inc. Class H (6185) Receives a Buy from UBS

In a report released on June 25, from UBS maintained a Buy rating on CanSino Biologics, Inc. Class H, with a price target of HK$52.40. The company’s shares closed yesterday at HK$21.34.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

CanSino Biologics, Inc. Class H has an analyst consensus of Moderate Buy, with a price target consensus of HK$52.40.

### Related Stocks

- [06185.HK](https://longbridge.com/en/quote/06185.HK.md)
- [688185.CN](https://longbridge.com/en/quote/688185.CN.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)

## Related News & Research

- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)
- [CanSino Biologics partners with deepGeneAI to develop personalized mRNA cancer vaccines](https://longbridge.com/en/news/297025441.md)
- [CSC Financial Reaffirms Their Buy Rating on Binjiang Service Group Co. Ltd. (3316)](https://longbridge.com/en/news/296861671.md)
- [CICC Keeps Their Buy Rating on J&T Global Express Limited (1519)](https://longbridge.com/en/news/296693029.md)
- [CanSinoBIO, deepGeneAI sign framework pact to develop personalized mRNA cancer vaccines](https://longbridge.com/en/news/296884268.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**